Singapore markets closed
  • Straits Times Index

    3,157.97
    -4.53 (-0.14%)
     
  • Nikkei

    28,948.73
    -9.83 (-0.03%)
     
  • Hang Seng

    28,842.13
    +103.25 (+0.36%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • BTC-USD

    35,975.05
    +222.23 (+0.62%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • Dow

    34,479.60
    +13.36 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.09 (+0.35%)
     
  • Gold

    1,879.50
    -16.90 (-0.89%)
     
  • Crude Oil

    70.78
    +0.49 (+0.70%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • FTSE Bursa Malaysia

    1,575.16
    -4.74 (-0.30%)
     
  • Jakarta Composite Index

    6,095.50
    -12.04 (-0.20%)
     
  • PSE Index

    6,907.79
    +32.08 (+0.47%)
     

Genenta to present at upcoming scientific congresses

·2-min read

ASGCT – ASCO – EHA

MILAN, Italy and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced it will be presenting at several upcoming scientific congresses in May and June.

Details of the presentations are as follows:

American Society of Cell and Gene Therapy (ASGCT) 24th Annual Meeting, May 11-14, virtual

Title: Changes in the Tumor Microenvironment in Patients with Glioblastoma Multiforme Treated with IFN-a Immune Cell & Gene Therapy (TEM-GBM_001 Study)
Type: Oral presentation
Time: Friday May 14, 1.30-1.45 PM CET

2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, virtual

Title: A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study)
Type: Poster presentation
Day: June 4

European Hematology Association (EHA) 2021 Virtual Congress, June 9-17, virtual

Title: A Phase I-IIA Study of Genetically Modified TIE-2 Expressing Monocytes in Patients with Glioblastoma Multiforme (TEM-GBM Study)
Type: Oral presentation
Time: Sunday June 13, 7.45-8.30 PM CET

About Genenta Science

Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). Temferon™, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and has been designed to reach solid tumors, one of the main unresolved challenge in immuno-oncology. Based in Milan, Italy, and New York, USA, Genenta has raised more than €33.6 million (~$40 million) in three separate rounds of financing.

Investor Relator - LifeSci Advisors:

Genenta Media/Investor Contact:

GENENTA SCIENCE Srl

Mary-Ann Chang, CFA

Stefania Mazzoleni, PhD

OSR - DiBit 1 - Via Olgettina, 58 - 20132 Milan (Italy)

+44 7483 28.48.53

+39 339 709.59.31

LaunchLabs - Alexandria Center, 14th Floor

mchang@lifesciadvisors.com

stefania.mazzoleni@genenta.com

430 East 29th Street - New York, NY 10016 (USA)